Successful Protection against Tularemia in C57BL/6 Mice Is Correlated with Expansion of Francisella tularensis-Specific Effector T Cells

ABSTRACT Francisella tularensis is an intracellular, Gram-negative bacterium that causes the fatal disease tularemia. Currently, there are no licensed vaccines for tularemia and the requirements for protection against infection are poorly defined. To identify correlates of vaccine-induced immunity against tularemia, we compared different strains of the live vaccine strain (LVS) for their relative levels of virulence and ability to protect C57BL/6 mice against challenge with virulent F. tularensis strain SchuS4. Successful vaccination, as defined by survival of C57BL/6 mice, was correlated with significantly greater numbers of effector T cells in the spleen and lung. Further, lung cells and splenocytes from fully protected animals were more effective than lung cells and splenocytes from vaccinated but nonimmune animals in limiting intracellular replication of SchuS4 in vitro. Together, our data provide a unique model to compare efficacious vaccines to nonefficacious vaccines, which will enable comprehensive identification of host and bacterial components required for immunization against tularemia.

[1]  D. Crane,et al.  Alternative Activation of Macrophages and Induction of Arginase Are Not Components of Pathogenesis Mediated by Francisella Species , 2013, PloS one.

[2]  Sang-Nae Cho,et al.  Differentiation of Antigen-Specific T Cells with Limited Functional Capacity during Mycobacterium tuberculosis Infection , 2013, Infection and Immunity.

[3]  D. Crane,et al.  Lipids Derived from Virulent Francisella tularensis Broadly Inhibit Pulmonary Inflammation via Toll-Like Receptor 2 and Peroxisome Proliferator-Activated Receptor α , 2013, Clinical and Vaccine Immunology.

[4]  D. Thanassi,et al.  FeoB-Mediated Uptake of Iron by Francisella tularensis , 2013, Infection and Immunity.

[5]  O. Foreman,et al.  IL‐12Rβ2 is critical for survival of primary Francisella tularensis LVS infection , 2013, Journal of leukocyte biology.

[6]  J. Celli,et al.  Mechanisms of Francisella tularensis intracellular pathogenesis. , 2013, Cold Spring Harbor perspectives in medicine.

[7]  D. Crane,et al.  B1a Cells Enhance Susceptibility to Infection with Virulent Francisella tularensis via Modulation of NK/NKT Cell Responses , 2013, The Journal of Immunology.

[8]  Wangxue Chen,et al.  BALB/c mice, but not C57BL/6 mice immunized with a ΔclpB mutant of Francisella tularensis subspecies tularensis are protected against respiratory challenge with wild-type bacteria: association of protection with post-vaccination and post-challenge immune responses. , 2012, Vaccine.

[9]  S. Kathariou,et al.  Purine biosynthesis mutants (purA and purB) of serotype 4b Listeria monocytogenes are severely attenuated for systemic infection in intragastrically inoculated A/J Mice. , 2012, Foodborne pathogens and disease.

[10]  D. Crane,et al.  Generation of a Convalescent Model of Virulent Francisella tularensis Infection for Assessment of Host Requirements for Survival of Tularemia , 2012, PloS one.

[11]  K. Elkins,et al.  Immunity to Francisella , 2011, Front. Microbio..

[12]  D. Crane,et al.  Long lived protection against pneumonic tularemia is correlated with cellular immunity in peripheral, not pulmonary, organs. , 2010, Vaccine.

[13]  G. Nau,et al.  Francisella tularensis ΔpyrF Mutants Show that Replication in Nonmacrophages Is Sufficient for Pathogenesis In Vivo , 2010, Infection and Immunity.

[14]  C. Bosio,et al.  The Presence of CD14 Overcomes Evasion of Innate Immune Responses by Virulent Francisella tularensis in Human Dendritic Cells In Vitro and Pulmonary Cells In Vivo , 2009, Infection and Immunity.

[15]  I. Golovliov,et al.  Identification of Genes Contributing to the Virulence of Francisella tularensis SCHU S4 in a Mouse Intradermal Infection Model , 2009, PloS one.

[16]  J. Celli,et al.  Direct and Indirect Impairment of Human Dendritic Cell Function by Virulent Francisella tularensis Schu S4 , 2008, Infection and Immunity.

[17]  D. Metzger,et al.  An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain. , 2008, Vaccine.

[18]  K. Elkins,et al.  The membrane form of tumor necrosis factor is sufficient to mediate partial innate immunity to Francisella tularensis live vaccine strain. , 2008, The Journal of infectious diseases.

[19]  Nita H. Salzman,et al.  A Francisella tularensis Schu S4 Purine Auxotroph Is Highly Attenuated in Mice but Offers Limited Protection against Homologous Intranasal Challenge , 2008, PloS one.

[20]  K. Elkins,et al.  Innate and Adaptive Immunity to Francisella , 2007, Annals of the New York Academy of Sciences.

[21]  Wangxue Chen,et al.  Oral immunization of mice with the live vaccine strain (LVS) of Francisella tularensis protects mice against respiratory challenge with virulent type A F. tularensis. , 2007, Vaccine.

[22]  J. Belisle,et al.  Active Suppression of the Pulmonary Immune Response by Francisella tularensis Schu41 , 2007, The Journal of Immunology.

[23]  J. Celli,et al.  Construction and Characterization of an Attenuated Purine Auxotroph in a Francisella tularensis Live Vaccine Strain , 2006, Infection and Immunity.

[24]  Wangxue Chen,et al.  Low dose aerosol infection of mice with virulent type A Francisella tularensis induces severe thymus atrophy and CD4+CD8+ thymocyte depletion. , 2005, Microbial pathogenesis.

[25]  J. Whitton,et al.  Cutting Edge: Early IFN-γ Signaling Directly Enhances Primary Antiviral CD4+ T Cell Responses1 , 2005, The Journal of Immunology.

[26]  Terry H Wu,et al.  Intranasal Vaccination Induces Protective Immunity against Intranasal Infection with Virulent Francisella tularensis Biovar A , 2005, Infection and Immunity.

[27]  J. Whitton,et al.  Interferon-γ acts directly on CD8+ T cells to increase their abundance during virus infection , 2005, The Journal of experimental medicine.

[28]  Wangxue Chen,et al.  Aerosol-, but not intradermal-immunization with the live vaccine strain of Francisella tularensis protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an alphabeta T cell- and interferon gamma- dependent mechanism. , 2005, Vaccine.

[29]  Wangxue Chen,et al.  Susceptibility of various mouse strains to systemically- or aerosol-initiated tularemia by virulent type A Francisella tularensis before and after immunization with the attenuated live vaccine strain of the pathogen. , 2004, Vaccine.

[30]  S. Way,et al.  Characterization of flagellin expression and its role in Listeria monocytogenes infection and immunity , 2004, Cellular microbiology.

[31]  Wangxue Chen,et al.  Tularemia in BALB/c and C57BL/6 mice vaccinated with Francisella tularensis LVS and challenged intradermally, or by aerosol with virulent isolates of the pathogen: protection varies depending on pathogen virulence, route of exposure, and host genetic background. , 2003, Vaccine.

[32]  M. Dorf,et al.  Differential Roles of CC Chemokine Ligand 2/Monocyte Chemotactic Protein-1 and CCR2 in the Development of T1 Immunity1 , 2002, The Journal of Immunology.

[33]  Philip K. Russell,et al.  Tularemia as a biological weapon: medical and public health management. , 2001, JAMA.

[34]  W. Kuziel,et al.  CCR2 Expression Determines T1 Versus T2 Polarization During Pulmonary Cryptococcus neoformans Infection1 , 2000, The Journal of Immunology.

[35]  A. Kamath,et al.  Molecular cloning and functional analysis of a novel macrolide‐resistance determinant, mefA, from Streptococcus pyogenes , 1996, Molecular microbiology.

[36]  K. Elkins,et al.  Minimal requirements for murine resistance to infection with Francisella tularensis LVS , 1996, Infection and immunity.

[37]  F. Nano,et al.  Phase variation in Francisella tularensis affecting intracellular growth, lipopolysaccharide antigenicity and nitric oxide production , 1996, Molecular microbiology.

[38]  W. R. Griffith,et al.  Aerogenic Immunization of the Monkey and Guinea Pig with Live Tularemia Vaccine , 1961, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[39]  H. T. Eigelsbach,et al.  Prophylactic effectiveness of live and killed tularemia vaccines. I. Production of vaccine and evaluation in the white mouse and guinea pig. , 1961, Journal of immunology.

[40]  F. McCrumb,et al.  AEROSOL INFECTION OF MAN WITH PASTEURELLA TULARENSIS. , 1961, Bacteriological reviews.

[41]  H. Wilson,et al.  Tularemia vaccine study. II. Respiratory challenge. , 1961, Archives of internal medicine.

[42]  S. Tasker,et al.  Bergey’s Manual of Systematic Bacteriology , 2010 .

[43]  J. Whitton,et al.  Cutting edge: early IFN-gamma signaling directly enhances primary antiviral CD4+ T cell responses. , 2005, Journal of immunology.

[44]  Robert E. Whitson,et al.  AN IMPROVED , 2005 .

[45]  R. Spencer,et al.  Six Additional Cases of Laboratory Infection of Tularæmia in Man , 1926 .